Pharmaceuticals News and Research

RSS

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for CF101 in the treatment of psoriasis.

17 Feb 2015

Lakeland Pharmacy seeks DAPA certification to pursue government procurement opportunities

Lakeland Pharmacy, a leading full-service pharmacy, pharmaceutical compounding shop, and medical device retailer, announced plans today to expand sales of their home respiratory equipment by applying for a Distribution and Pricing Agreement (DAPA) certification and actively pursuing government procurement opportunities.

17 Feb 2015

Astrazeneca adopts Labguru software for global management of biological research reagents

BioData, producer of Labguru, the web-based research and lab management system, today announced that the Innovative Medicines unit of global pharmaceutical business, AstraZeneca, has adopted the Labguru platform for the global management of biological reagents used in pre-clinical research.

17 Feb 2015

Novartis’ heart failure medicine LCZ696 granted FDA priority review

LCZ696, a twice-a-day medicine being investigated for heart failure, acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).

16 Feb 2015

R. Bryan Miller Symposium to spotlight special focus on rare disease research

The University of California, Davis Department of Chemistry will spotlight a special focus on rare disease research with this year's 15th annual R. Bryan Miller Symposium. Experts in rare diseases will gather at the UC Davis Conference Center March 5 for a conference highlighting the opportunities and challenges in applying cutting edge technologies and "precision medicine" to better treat conditions that together affect millions of people, especially children.

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

Experts discuss therapeutic potential of medical cannabis in a symposium organized by MUHC

While debate about recreational marijuana use continues, researchers are investigating the effectiveness of cannabis for treating pain, spasticity, and a host of other medical problems. In a symposium organized by the McGill University Health Centre as part of the 2015 American Association for the Advancement of Science Annual Meeting held this week in San Jose, California, world-renowned experts from North America and the U.K. share their perspectives on the therapeutic potential of medical cannabis and explore the emerging science behind it.

16 Feb 2015

Imperial College London to invest in new facility at Babraham Campus to support dynamic bioscience companies

Imperial College London is to invest in a new facility at the Babraham Research Campus in Cambridge to support spin-out and scale-up companies, and maximise the impact of research from universities.

From Abzena 13 Feb 2015

Landmark stroke studies presented at ISC, published in NEJM suggest new treatment protocol on the horizon

Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire™ Device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke.

From Medtronic 13 Feb 2015

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.

13 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

Research report on global market for cell-based assays

BioInformatics LLC has announced the release of their latest report, The Market for Cell-Based Assays.

13 Feb 2015

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by Health Canada.

13 Feb 2015

AMRI optimizes global operations to improve continuous supply chain across its businesses

AMRI today announced that it has implemented several changes to further optimize global business operations in order to enhance continuity from early development through to commercial supply and accelerate the company's global growth objectives.

12 Feb 2015

Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

A new whitepaper from Malvern Panalytical provides detailed guidance on the analytical technologies that help to accelerate oral solid dosage (OSD) product formulation to a successful conclusion.

From Malvern Panalytical 12 Feb 2015

AMRI reports financial and operating results for Q4 and FY 2014

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2014.

12 Feb 2015

Hospira announces record fourth-quarter and FY 2014 results

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the fourth quarter and full year ended Dec. 31, 2014.

12 Feb 2015

Breckenridge files Paragraph IV ANDA litigation with Sanofi for generic version of Jevtana

Breckenridge Pharmaceutical, Inc. announced today that it has filed an ANDA with a Paragraph IV certification for cabazitaxel solution; IV (infusion) in 60 mg/1.5 mL (40 mg/mL) strength, a generic version of Jevtana® by Sanofi.

12 Feb 2015

World Courier opens new distribution facility in Melbourne, Australia

World Courier, the global leader in specialty logistics and an AmerisourceBergen company, has opened the doors to its new distribution facility in Melbourne, Australia.

12 Feb 2015

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.

12 Feb 2015

Pharmaceuticals News and Research

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Lakeland Pharmacy seeks DAPA certification to pursue government procurement opportunities

Astrazeneca adopts Labguru software for global management of biological research reagents

Novartis’ heart failure medicine LCZ696 granted FDA priority review

R. Bryan Miller Symposium to spotlight special focus on rare disease research

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Experts discuss therapeutic potential of medical cannabis in a symposium organized by MUHC

Imperial College London to invest in new facility at Babraham Campus to support dynamic bioscience companies

Landmark stroke studies presented at ISC, published in NEJM suggest new treatment protocol on the horizon

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Research report on global market for cell-based assays

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

AMRI optimizes global operations to improve continuous supply chain across its businesses

Analytical strategies that support OSD formulation: A new whitepaper from Malvern Instruments

AMRI reports financial and operating results for Q4 and FY 2014

Hospira announces record fourth-quarter and FY 2014 results

Breckenridge files Paragraph IV ANDA litigation with Sanofi for generic version of Jevtana

World Courier opens new distribution facility in Melbourne, Australia

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence